---
title: "Mingteng International Raises US$18 Million Via ATM Share Sales, Leaves US$79.4 Million Capacity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273283817.md"
description: "Mingteng International Corp. has raised approximately US$18 million through an at-the-market (ATM) equity offering program, having issued 222,568,877 Class A shares. The company retains US$79.4 million in capacity under the ATM program, which it plans to use for general corporate purposes, including working capital and business development. The latest analyst rating for MTEN stock is a Hold with a price target of $0.03, reflecting concerns over financial quality and technical performance."
datetime: "2026-01-21T21:36:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273283817.md)
  - [en](https://longbridge.com/en/news/273283817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273283817.md)
---

# Mingteng International Raises US$18 Million Via ATM Share Sales, Leaves US$79.4 Million Capacity

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Mingteng International Corp., Inc. ( (MTEN) ) has shared an announcement.

On December 4, 2025, Mingteng International Corporation Inc. entered into a US$100 million at-the-market (ATM) equity offering program with AC Sunshine Securities LLC as sales agent, enabling the company to sell Class A ordinary shares under its existing U.S. shelf registration. By January 21, 2026, Mingteng had issued 222,568,877 Class A ordinary shares through this facility, raising about US$20.6 million in gross proceeds and approximately US$18.0 million in net proceeds after commissions and expenses, bringing its total outstanding Class A shares to 242,334,931. The company retains roughly US$79.4 million in remaining capacity under the ATM program, which remains active, and plans to deploy the new capital for general corporate purposes, including working capital, business development initiatives and capital expenditures, signaling an ongoing effort to strengthen its balance sheet and fund growth initiatives through incremental equity issuance.

The most recent analyst rating on (MTEN) stock is a Hold with a $0.03 price target. To see the full list of analyst forecasts on Mingteng International Corp., Inc. stock, see the MTEN Stock Forecast page.

**Spark’s Take on MTEN Stock**

According to Spark, TipRanks’ AI Analyst, MTEN is a Neutral.

The score is primarily pressured by weak financial quality (negative margins and declining free cash flow) and very bearish technicals (deeply below moving averages with negative MACD). Valuation provides limited support because the P/E is negative due to losses and no dividend yield is available.

To see Spark’s full report on MTEN stock, click here.

**More about Mingteng International Corp., Inc.**

Mingteng International Corporation Inc. is a foreign private issuer headquartered in Wuxi, Jiangsu Province, China, and its Class A ordinary shares are listed in the United States, where it accesses U.S. capital markets under an effective shelf registration on Form F-3.

**Average Trading Volume:** 31,301,540

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $215.6K

For an in-depth examination of MTEN stock, go to TipRanks’ Overview page.

### Related Stocks

- [MTEN.US](https://longbridge.com/en/quote/MTEN.US.md)

## Related News & Research

- [How Is Vulcan Materials' Stock Performance Compared to Other Building & Construction Stocks?](https://longbridge.com/en/news/289334263.md)
- [How Is Howmet Aerospace's Stock Performance Compared to Other Aerospace & Defense Stocks?](https://longbridge.com/en/news/289366384.md)
- [Crocs (CROX) Taps ESOP Shelf Offering As Analyst Upgrade Tests The Brand Durability Narrative](https://longbridge.com/en/news/289276367.md)
- [Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility | ODYS Stock News](https://longbridge.com/en/news/288974123.md)
- [Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?](https://longbridge.com/en/news/289030593.md)